StockData
Cytokinetics Inc logo

Cytokinetics Inc (CYTK) stock

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30
$62.99−0.32 (-0.51%)

Close on Oct 30, 2026Market cap $8.76BP/E –Yield –

Earnings

Cytokinetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$28.60M
-57.2% on a year earlier
EPS, Q2 FY2026
-$1.50
Latest guidance
Raised
Aug 6, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Cytokinetics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$28.60M-57.2%-$1.50Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$19.40M+1112.5%-$1.67Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026after the close$17.80M+5.3%-$1.50Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$1.90M–-$2.55Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$66.80M+33300.0%–Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$1.60M+100.0%-$1.36Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$16.90M+894.1%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$200.00K-77.8%-$1.31Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$800.00K-82.6%-$1.33Release
Q4 FY2023ended Dec 31, 2023Feb 27, 2024after the close$1.70M-15.0%-$1.38Release
Q3 FY2023ended Sep 30, 2023Nov 2, 2023after the close$400.00K-84.0%-$1.35Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Cytokinetics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GAAP combined R&D and SG&A ExpenseGAAPFY2026$860.00M – $890.00M$830.00M – $870.00MRaisedAug 6, 2026
Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expensenon-GAAPFY2026$130.00M – $140.00M–NewAug 6, 2026
Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00M$120.00M – $130.00MReaffirmedMay 5, 2026

Guidance history

Every forecast Cytokinetics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A ExpenseFY2026$130.00M – $140.00MNew
Aug 6, 2026GAAP combined R&D and SG&A ExpenseFY2026$860.00M – $890.00MRaised
May 5, 2026GAAP Combined R&D and SG&A ExpenseFY2026$830.00M – $870.00MReaffirmed
May 5, 2026Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00MReaffirmed
Feb 24, 2026Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00MNew
Feb 24, 2026GAAP Combined R&D and SG&A ExpenseFY2026$830.00M – $870.00MNew
Nov 5, 2025Non-cash stock-based compensation expense included in GAAP operating expenseFY2025$110.00M – $120.00MNew
Nov 5, 2025GAAP operating expenseFY2025$680.00M – $700.00MNew
May 6, 2025GAAP operating expenseFY2025$670.00M – $710.00MNew
May 6, 2025Non-cash stock-based compensation expense included in GAAP operating expenseFY2025$110.00M – $120.00MNew
Aug 8, 2024Non-cash Expense Included in GAAP Operating ExpenseFY2024$105.00M – $110.00MLowered
Aug 8, 2024GAAP Operating ExpenseFY2024$555.00M – $575.00MNew
Aug 8, 2024Non-GAAP Operating ExpenseFY2024$445.00M – $470.00MNew
Aug 8, 2024Net Cash UtilizationFY2024$400.00M – $420.00MLowered
Feb 27, 2024operating expensesFY2024$420.00M – $450.00MNew
Feb 27, 2024net cash utilizationFY2024$390.00M – $420.00MLowered
Feb 27, 2024revenueFY2024$3.00M – $5.00MNew
Aug 3, 2023operating expensesFY2023$390.00M – $410.00MRaised
Aug 3, 2023net cash utilizationFY2023$310.00M – $320.00MLowered
Mar 1, 2023milestone paymentFY2023$50.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Cytokinetics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Cytokinetics Announces Positive Results from ACACIA-HCM
    News
  2. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
    Results
  3. 8-K exhibit EX-99.1
    News
  4. Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
    Results
  5. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
    Results
  6. CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
    Results
  7. Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
    News
  8. Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
    News
  9. CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN
    News
  10. CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN
    News
  11. CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM MAPLE-HCM
    News
  12. CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
    Results
  13. CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
    Results
  14. CYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
    Results
  15. CYTOKINETICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
    Results